<p>Berkeley biotech’s stem cell rejuvenation platform, built for transplant medicine, is branching into an injectable and a skin treatment. A little over a year ago, HexemBio was a single-idea company: take a patient’s own aging blood stem cells, briefly place them back in a lab-built version of the en</p>